{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:39:21Z","timestamp":1778675961739,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Genetics"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.cancergen.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,8,17]],"date-time":"2016-08-17T07:19:44Z","timestamp":1471418384000},"page":"554-558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The pathways of genetic transformation in cholangiocarcinogenesis"],"prefix":"10.1016","volume":"209","author":[{"given":"Francesco M.","family":"Serafini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Radvinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergen.2016.07.004_bib0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/s-2007-1007302","article-title":"Recent advances in the management of cholangiocarcinomas","volume":"14","author":"Vauthey","year":"1994","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0015","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2005.03.040","article-title":"Cholangiocarcinoma","volume":"128","author":"Lazaridis","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-2004-828889","article-title":"The epidemiology of cholangiocarcinoma","volume":"24","author":"Shaib","year":"2004","journal-title":"Semin Liver Dis"},{"issue":"suppl 6","key":"10.1016\/j.cancergen.2016.07.004_bib0025","first-page":"S1","article-title":"Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document","volume":"51","author":"Khan","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0030","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1245\/s10434-010-1325-4","article-title":"Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma","volume":"18","author":"Marukami","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrgastro.2011.20","article-title":"Cholangiocarcinoma\u2014controversies and challenges","volume":"8","author":"Patel","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0040","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1371\/journal.pmed.0040201","volume":"4","author":"Sripa","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0045","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4251\/wjgo.v2.i3.136","article-title":"New insights on cholangiocarcinoma","volume":"2","author":"Gatto","year":"2010","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0050","doi-asserted-by":"crossref","first-page":"10517","DOI":"10.1158\/0008-5472.CAN-06-2130","article-title":"IL-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression","volume":"66","author":"Wehbe","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep.20537","article-title":"Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy","volume":"41","author":"Sirica","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0060","first-page":"477","article-title":"Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma","volume":"79","author":"Kang","year":"1999","journal-title":"Lab Invest"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0065","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0215(19981209)78:6<695::AID-IJC5>3.0.CO;2-8","article-title":"Alterations of the p53 tumor-suppression gene and K-Ras oncogene in peri-hilar cholangiocarcinomas from high-incidence area","volume":"78","author":"Sturm","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0070","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/mc.2940080415","article-title":"Mutations of the p53 tumor suppressor gene and ras gene family in intrahepatic cholangiocellular cancer in Japan and Thailand","volume":"8","author":"Kiba","year":"1993","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0075","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2353\/jmoldx.2010.100016","article-title":"Comparison of KRAs mutation analysis and FISH for detecting pancreaticobiliary tract cancer in cytology specimens collected during ERCP","volume":"12","author":"Kipp","year":"2010","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0080","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/path.1779","article-title":"Amplification and expression of c-erbB-2 EPGF receptor and c-met in biliary cancers","volume":"3","author":"Nakazawa","year":"2005","journal-title":"J Pathol"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0085","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/1078-0432.CCR-08-0905","article-title":"Mutations and response to EPGW receptor inhibitors","volume":"15","author":"Laurent Puig","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0090","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/0008-5472.CAN-11-3596","article-title":"Kras and p53 mutation cause primary intrahepatic cholangiocarcinoma","volume":"72","author":"O'Dell","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0095","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10620-010-1352-9","article-title":"P53 status and its prognostic role in extrahepatic bile duct cancers: a meta-analysis of published studies","volume":"56","author":"Wang","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0100","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.3760\/cma.j.issn.0366-6999.20121235","article-title":"Inactivation of SMAD4 is a prognostic factor for intrahepatic cholangiocarcinoma","volume":"126","author":"Yan","year":"2013","journal-title":"Chin Med J"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0105","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.3748\/wjg.14.2990","article-title":"C-Met targeted therapy of cholangiocarcinoma","volume":"14","author":"Socotenau","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0110","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0046-8177(98)90229-5","article-title":"Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and hepatolithiasis","volume":"29","author":"Terada","year":"1998","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0115","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0120","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/j.gastro.2011.12.005","article-title":"Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets of TKI","volume":"142","author":"Andersen","year":"2012","journal-title":"Gastroenterolgy"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0125","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0092-8674(92)90611-F","article-title":"Targeted mutation of the DNA methyltransferase gene results in embryonic lethality","volume":"69","author":"Li","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1101\/gad.947102","article-title":"DNA methylation patterns and epigenetic memory","volume":"16","author":"Bird","year":"2002","journal-title":"Genes Dev"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0135","series-title":"Advances in Cancer Research","first-page":"141","article-title":"Alterations in DNA methylation: a fundamental aspect of neoplasia","author":"Baylin","year":"1998"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0140","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/366704a0","article-title":"A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D\/CDK4","volume":"366","author":"Serrano","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0145","doi-asserted-by":"crossref","first-page":"923","DOI":"10.5858\/2007-131-923-MPOMCI","article-title":"Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those intrahepatic cholangiocarcinoma","volume":"131","author":"Kim","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0150","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0002-9440(10)64262-9","article-title":"Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma","volume":"161","author":"Lee","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(02)00269-6","article-title":"Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma","volume":"37","author":"Wong","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0160","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/modpathol.3800287","article-title":"Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma","volume":"18","author":"Yang","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0165","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0170","first-page":"808","article-title":"Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines","volume":"57","author":"Kane","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0175","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.canlet.2004.06.020","article-title":"Promoter hypermethylation is a major event of hMLH1 gene inactivation in liver fluke related cholangiocarcinoma","volume":"217","author":"Limpaibon","year":"2005","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0180","first-page":"371","article-title":"Deficient expression of (6)-methylguanine-DNA methyltransferase combined with mismatched-repair proteins hMLH1 and hMLH2 is related to poor prognosis in human biliary tract carcinoma","volume":"9","author":"Koya","year":"2002","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0185","article-title":"Correlation between promoter methylation of p14(ARF), TMS1\/ASC, and DAPK, and p53 mutation with prognosis in cholangiocarcinoma","volume":"10","author":"Xiofang","year":"2012","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0190","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.onc.1209808","article-title":"NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB2","volume":"26","author":"Chua","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0195","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/ni931","article-title":"SOCS3 negatively regulates IL-6 signaling in vivo","volume":"4","author":"Croker","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0200","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/j.gastro.2006.10.037","article-title":"Sustained IL-6\/STAT-3 signaling in cholangiocarcinoma cells due to SOCS3 epigenetic silencing","volume":"132","author":"Isomoto","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0205","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/path.1139","article-title":"Genetic and epigenetic alterations of the p14ARF pathway in cholangiocarcinoma","volume":"197","author":"Tannapfel","year":"2002","journal-title":"J Pathol"},{"issue":"suppl 1","key":"10.1016\/j.cancergen.2016.07.004_bib0210","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/s002800100322","article-title":"Histone deacetylase and transcriptional therapy with their inhibitors","volume":"48","author":"Pandolfi","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0215","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1074\/jbc.M607712200","article-title":"The micro-RNA let-7a modulates interleukin-6 dependent STAT-3 survival signaling in malignant human cholangiocytes","volume":"282","author":"Meng","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0220","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1053\/j.gastro.2012.03.045","article-title":"MicroRNA-26a promotes cholangiocarcinoma growth by activating b-catenin","volume":"143","author":"Zhang","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0225","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0230","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/sj.bjc.6604988","article-title":"Vandetanib (ZD6474) an inhibitor of VEGFR and EGFR signaling as a novel molecular-targeted therapy against cholangiocarcinoma","volume":"100","author":"Yoshikawa","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0235","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/j.gastro.2011.12.005","article-title":"Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors","volume":"142","author":"Andersen","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0240","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/11318860-000000000-00000","article-title":"Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the near of molecular cancer therapies","volume":"23","author":"Papaetis","year":"2009","journal-title":"Biodrugs"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0245","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multilines inhibitor of angiogenic, stream and oncogenic receptor tyrosine kinase with potent preclinical antitumor activities","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cancergen.2016.07.004_bib0250","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12272-015-0569-8","article-title":"IL-6 inhibitors for the treatment of rheumatoid arthritis: past, present and future","volume":"38","author":"Kim","year":"2015","journal-title":"Arch Pharm Res"}],"container-title":["Cancer Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776216302241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776216302241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:41:25Z","timestamp":1761896485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210776216302241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S2210776216302241"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergen.2016.07.004","relation":{},"ISSN":["2210-7762"],"issn-type":[{"value":"2210-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pathways of genetic transformation in cholangiocarcinogenesis","name":"articletitle","label":"Article Title"},{"value":"Cancer Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cancergen.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}